其中一个已被考虑的因素是味觉变化,这是一种与药物本身相关的特殊特征。根据其包装说明书,已知以下药物会导致味觉异常:吸入性糖皮质激素(ICS)、ICS与长效β-受体激动剂(LABA)的复方,以及抗胆碱能药物。最近,有报道称某些味觉受体(尤其...
Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis. 2017;12:1877-1882.Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAM...
The results are promising and favor the LAMA/LABA inhalers, especially in the longer duration trials. Furthermore, there is a clearer picture emerging as to the subgroup of COPD patients who may be able to successfully switch from their current ICS/LABA therapy to these new LAMA/LABA inhaler...
The search terms were "COPD" AND inhaled drugs ("LAMA" AND "LABA") AND randomized controlled design, which included controlled vocabulary and free text. The LAMAs included aclidinium, glycopyrrolate, tiotropium with a dry powder inhaler or soft mist inhaler, and ume- clidinium. The LABAs ...
Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). However, it is still unclear whether LABA or LAMA should be used for the initial treatment. ...
With multiple add-on therapies available for the management of asthma, there have been several systematic reviews published that evaluate the efficacy and safety of add-on therapies compared with either placebo or another add-on therapy14,15,16,17,19,20. However, none compare LABA, LTRA and L...
10 LAMA/LABA FDCs also improve both transitional dyspnea index and St. George’s Respiratory Questionnaire scores. Furthermore, there is also clear evidence that when the goal of the therapy is to enhance exercise capacity in patients with COPD, LAMA/LABA FDCs consistently meet the putative ...
And Then There Were Three: Time to Move Onward in COPD Drug Development Beyond LAMA/LABA/ICS at Last?doi:10.1007/s41030-018-0059-5COPDIMPACTInhaled corticosteroidsInhaler combinationsLAMA/LABA/ICSTRIBUTEKai M. BeehInsaf Respiratory Research InstitutePulmonary Therapy...
GFF MDI (Bevespi Aerosphere®) is a fixed-dose combination (FDC) of GP (14.4 μg) and the LABA formoterol fumarate dihydrate (FF; 10 μg), delivered by a metered dose inhaler (MDI) using innovative co-suspension delivery technology [[17], [18], [19]]. GFF MDI is the first...
Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2021. [cited 2022 July 1]. Available from:https://goldcopd.org/ Google Scholar Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy ...